Premium
Role of Lactobacillus in the Prevention of Antibiotic‐Associated Diarrhea: A Meta‐analysis
Author(s) -
KalePradhan Pramodini B.,
Jassaly Harjot K.,
Wilhelm Sheila M.
Publication year - 2010
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.30.2.119
Subject(s) - jadad scale , medicine , placebo , antibiotic associated diarrhea , regimen , lactobacillus , diarrhea , probiotic , randomized controlled trial , antibiotics , meta analysis , lactobacillus fermentum , cochrane library , lactobacillus plantarum , microbiology and biotechnology , biology , alternative medicine , pathology , lactic acid , genetics , clostridium difficile , bacteria
Study Objective. To evaluate the efficacy of a Lactobacillus probiotic singleagent regimen in preventing antibiotic‐associated diarrhea (AAD). Design. Meta‐analysis of 10 randomized, blinded, placebo‐controlled trials. Patients. A total of 1862 pediatric and adult patients who received a Lactobacillus single‐agent regimen or placebo for the prevention of AAD. Measurements and Main Results. The MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched from inception through May 2008 by two investigators independently using the following key words: probiotic, Lactobacillus , antibiotic‐associated diarrhea. Full reports published in English were included if the studies were randomized, blinded, and placebo‐controlled trials that evaluated the efficacy of Lactobacillus single‐agent regimens versus placebo in the prevention of AAD. Bibliographies of recent review articles and systematic reviews were hand searched. Quality of the studies was assessed by using the Jadad scoring system. Number of subjects, age, Lactobacillus regimen, follow‐up period, and occurrence of AAD were extracted into a standardized data collection form. Overall impact of Lactobacillus on AAD was compared with placebo by using a random‐effects model. Ten studies with a total of 1862 patients (50.4% male) met all criteria. Six studies included patients aged 18 years or older, whereas four included patients younger than 18 years (range 2 wks‐14 yrs). Jadad scores ranged from 2–5 (out of 5). The total daily dose of Lactobacillus ranged from 2 times 10 9 −4 times 10 10 colony‐forming units and was administered throughout the entire antibiotic treatment (5–14 days) for all patients. The follow‐up period varied from 2 days‐3 months after the end of the probiotic regimen. The combined risk ratio (RR) of developing AAD was significantly lower with Lactobacillus compared with placebo (RR 0.35, 95% confidence interval [CI] 0.19‐0.67). In a subgroup analysis, this held true for adults but not pediatric patients (RR 0.24, 95% CI 0.08‐0.75 and RR 0.44, 95% CI 0.18‐1.08, respectively). Conclusion. Administration of a Lactobacillus single‐agent regimen as a prophylactic agent during antibiotic treatment reduced the risk of developing AAD compared with placebo in adults but not pediatric patients.